Bristol-Myers Squibb Slashes FY26 EPS Outlook, But Raises Revenue Forecast - Update
Bristol-Myers Squibb (BMY) reported Q3 results, lowering FY26 EPS guidance to $6.35-$6.55 (prev. $6.75-$7.00) but raising revenue outlook to $49.75B-$50.25B (prev. $49.0B-$50.0B). The company cited IPRD charges and licensing income for the EPS adjustment. BMY shares rose 2.19% in pre-market trading.
How this was made
The 30-second read
Why it matters
Traders will likely focus on the EPS cut versus the revenue raise, and on how much of the EPS change is attributable to the stated IPRD and licensing income net impact.
Market read
A guidance update with explicit EPS and revenue ranges is a direct catalyst for repricing BMY’s earnings outlook and near-term sentiment.
What to watch
The guidance explicitly includes a $0.60 per share net impact from Acquired IPRD charges and licensing income, which could mean normalized earnings are less impaired than headline EPS suggests.
Background
Bristol-Myers Squibb reported Q3 results and issued updated full-year 2026 guidance.
Ticker impact
Bristol-Myers Squibb cut FY26 EPS guidance to about $6.35 to $6.55 while raising FY26 revenue to about $49.75B to $50.25B.
Likely downside bias as the market reprices earnings power after the EPS cut, partially offset by the higher revenue outlook.
The article reports a same-day guidance change with explicit EPS and revenue ranges, which typically drives immediate repricing; the EPS cut is the more direct earnings-power signal.
Market effects
Signals continued earnings pressure management in large-cap pharma, with investors focusing on non-operating items like IPRD charges.
Primarily US large-cap pharma sentiment, with limited direct spillover beyond the sector.
Moderate, as the guidance update is company-specific but can influence broader pharma earnings expectations.
Counterpoint
The revenue raise and continued Eliquis growth expectation may indicate the EPS softness is driven by identifiable accounting impacts rather than deteriorating underlying demand.
Key entities
- companyBristol-Myers Squibb Co.
Cut FY26 EPS outlook to about $6.35 to $6.55 and raised FY26 revenue outlook to about $49.75B to $50.25B; expects Eliquis revenues to grow 20% to 25% in 2026 vs 2025.
